Victoza

Question 1

What percentage of Bydureon patients had anti-exenatide antibodies associated with an attenuated glycemic response?

Answer 1

6%

Question 2

What percentage of Victoza-treated patients had anti-liraglutide antibody formation leading to neutralization of native GLP-1 in in vitro assays?

Answer 2

• 2.3% in 52 week trial
• 1.0% in 26 week trial

Question 3

What was the withdrawal rates in the Bydureon clinical trials?

Answer 3

• 4.9% for Bydureon patients
• 4.9& for Byetta patients
• 2.0% for comparator

Question 4

What were the withdrawal rates in the 8 Victoza clinical trials?

Answer 4

• 7.8% for Victoza patients
• 3.4% for comparator

Question 5

What percentage of Bydureon-treated patients in the add-on to metformin trial experienced nausea?

Answer 5

24.4%

Question 6

What percentage of Victoza-treated patients in the add-on to metformin trials experienced nausea?

Answer 6

15.2%

Question 7

Describe data on injection site nodules with Bydureon.

Answer 7

• 17% Bydureon patients vs. 2% Victoza patients experienced injection site nodules
• 1.0% of Bydureon patients withdrew due to injection site nodules versus 0.2% Victoza patients
• in a separate trial, 77% of Bydureon patients experienced at least one nodule during treatment with the mean duration being 27 days